About PGDx

Board of Directors

Luis Diaz
Luis Diaz, MD
Dr. Luis Diaz is a leading authority in oncology, having developed personalized diagnostic and therapeutic approaches for cancer. Dr. Diaz is a pioneer in circulating tumor DNA analyses in human cancer, having performed landmark studies in the field. Dr. Diaz is Head of the Division of Solid Tumor Oncology in Memorial Sloan Kettering’s Department of Medicine. He is also a medical oncologist who cares for people with advanced colon cancer and pancreatic cancer and a researcher applying cancer genetics to find new ways to diagnose and treat the disease.  Dr. Diaz has undergraduate and medical degrees from the University of Michigan, and completed post-doctoral training at Johns Hopkins University.
Justin Klein
Justin Klein, MD, JD

Justin joined NEA in 2006 and is a Partner on the healthcare team. He focuses on medical device, healthcare technology, and biopharmaceutical company investments.He serves as a director of Advanced Cardiac Therapeutics, Cartiva, ChromaCode, FIRE1, Intact Vascular, Personal Genome Diagnostics, PhaseBio Pharmaceuticals, Relievant Medsystems, Senseonics (NYSE: SENS), VertiFlex, Vesper Medical, and VytronUS. Justin’s past board memberships and investments include CV Ingenuity (acquired by Covidien), Nevro (NYSE: NVRO), Topera (acquired by Abbott), TriVascular (NASDAQ: TRIV), and Ulthera (acquired by Merz). He is also a member of the advisory boards for the National Venture Capital Association’s Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC), as well as a member of AdvaMed's Business Development Committee.

Prior to NEA, Justin worked for the Duke University Health System—reporting directly to the hospital CEO on health system strategy, finance, and clinical service unit operations—as Duke built one of the nation's first and largest healthcare integrated delivery systems. Justin concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School. He has also served as a member of the Board of Trustees of Duke University, where he earned his AB in Economics and his BS in Biological Anthropology and Anatomy.

James LaFrance
James LaFrance, MBA, CPA
Mr. James T. LaFrance, also known as Jim, serves as Chief Executive Officer and President of LaFrance Consulting. Mr. LaFrance served as the Chief Executive Officer and President of Vermillion, Inc., from April 2014 to December 2014. He served as an Acting Chief Executive Officer of Omnyx, LLC for GE Healthcare from January 2012 to October 2013. He served as Head of Digital Pathology at GE Healthcare. He has 30 years of diagnostic industry experience. From August 2009 to December 2011, he further served as a consultant in the medical diagnostics for LaFrance Consulting LLC. From 2001 to 2009, he held leadership positions at Ventana Medical Systems Inc. and served as its Vice President of Worldwide Marketing, Vice President of North America and Vice President of International Operations, during which he led the integration of Ventana into Roche Diagnostics. Mr. LaFrance spent 16 years with Bayer Diagnostics in various management roles, as Vice President of Marketing & Business Development - the global Near Patient Testing division. He ran his own management consultancy. He has been the Chairman at Vermillion, Inc. since December 12, 2013. He has been Director of HTG Molecular Diagnostics, Inc. since December 1, 2015. He served as a Director of Mitomics Inc. Mr. LaFrance has a BA in Economics from the University of Connecticut, MBA in Marketing and Finance from the University of Notre Dame and is a Certified Public Accountant.
Victor Velculescu
Victor Velculescu, MD, PhD
Dr. Victor Velculescu is internationally known for his discoveries in genomics and cancer research. He and his colleagues have pioneered a variety of genomic technologies and were the first to perform genome-wide sequence analyses in human cancer. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human tumors. He is Professor of Oncology and Co-Director of Cancer Biology at Johns Hopkins Kimmel Cancer Center. Dr. Velculescu has a B.S. from Stanford University, and MD, PhD degrees and postdoctoral training from Johns Hopkins University.
Douglas Ward
Douglas Ward
Chief Executive Officer
Mr. Doug Ward joined Personal Genome Diagnostics as Chief Executive Officer and a member of the board of directors in May 2016 from Roche, where he served as Vice President Companion Diagnostics (CDx) for Ventana Medical System. He has more than 25 years of experience within the diagnostic market and most recently has been responsible for creating Ventana’s CDx strategy, establishing Ventana’s innovative pharma partnering co-development business model, and achieving the market leading position in tissue based companion diagnostics. Prior to joining Roche, Mr. Ward served as President of the America’s Commercial Operations for GE Healthcare Life Sciences Business. Previously, he was Country Head of the UK and Ireland for Siemens Healthcare Diagnostics and Vice President of Marketing and Scientific Affairs for Bayer Diagnostics’ Molecular Diagnostics business unit. In addition, he has held leadership positions with Chiron Diagnostics and Ciba Corning Diagnostics. Doug received his BA from Ohio Wesleyan University in Pre-Medicine and Pre-Professional Zoology.